Texas A&M University Department of Biomedical Engineering, College Station, Texas, US.
Houston Methodist DeBakey Cardiovascular Surgery Associates, Houston, Texas, US.
Methodist Debakey Cardiovasc J. 2023 Mar 7;19(2):29-37. doi: 10.14797/mdcvj.1173. eCollection 2023.
Endovascular stent graft repair (EVAR) has revolutionized the management of aneurysms and dissections of the thoracic and abdominal aorta and is considered the first-line treatment in such pathologies. Initially designed for patients unfit for open repair, EVAR and thoracic endovascular aortic stent graft repair are associated with improved morbidity and mortality and a faster recovery process. The endovascular revolution of the aorta continues moving proximally, with fenestrated and branch stent grafts currently in clinical trials for the management of thoracoabdominal aortic aneurysms, and several branched thoracic devices are either approved or in trial for management of aortic arch pathologies. The final frontier in the endovascular management of the aorta is the aortic root and ascending aorta. The first early feasibility trial for management of type A aortic dissection has recently concluded with a multicenter phase 2 study slated for the spring of 2023. The following article updates the reader on the unique challenges of endovascular management of the ascending aorta and a look at the future technologies that will define this space.
血管内支架移植物修复(EVAR)彻底改变了胸主动脉和腹主动脉瘤的治疗方法,被认为是此类病变的一线治疗方法。最初设计用于不适合开放修复的患者,EVAR 和胸主动脉腔内支架移植物修复与改善发病率和死亡率以及更快的康复过程相关。主动脉的腔内革命继续向近端发展,目前正在进行用于治疗胸腹主动脉瘤的开窗和分支支架移植物的临床试验,并且几种分支型胸主动脉器械已获得批准或正在进行用于治疗主动脉弓病变的临床试验。主动脉腔内治疗的最后前沿是主动脉根部和升主动脉。最近完成了一项用于治疗 A 型主动脉夹层的首个早期可行性试验,多中心 2 期研究计划于 2023 年春季进行。本文将为读者更新有关升主动脉腔内管理的独特挑战的信息,并探讨未来将定义这一领域的技术。